Increased Arid5a levels in the CD4+ T-cells of untreated rheumatoid arthritis (RA) patients are reduced by the anti-IL-6 receptor antibody tocilizumab, implicating the contribution of the IL-6-ARID5A axis in RA pathogenesis [371]. This evidence concerns the gene ARID5A and rheumatoid arthritis.